Unveiling Multiple Endocrine Neoplasia Type 1 (MEN-1) in a Young Pakistani Male with Recurrent Hypoglycemia: A Diagnostic Odyssey in a Resource-Limited Setting
The case highlights the diagnostic challenges of MEN-1 in atypical presentations and resource-limited settings, underscoring the need for a multidisciplinary approach to treatment and psychosocial support.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:This case report describes a 32-year-old Pakistani male who was initially admitted to a tertiary care hospital with Typhoid fever, but later developed recurrent life-threatening hypoglycemia.
📊
Key Findings & Data:Extensive investigations revealed elevated insulin and C-peptide levels, a pituitary microadenoma, and a somatostatin-avid gastric lesion, leading to the diagnosis of Multiple Endocrine Neoplasia type 1 (MEN-1).
💡
Conclusion & Impact:The case highlights the diagnostic challenges of MEN-1 in atypical presentations and resource-limited settings, underscoring the need for a multidisciplinary approach to treatment and psychosocial support.
This case report describes a 32-year-old Pakistani male who was initially admitted to a tertiary care hospital with Typhoid fever, but later developed recurrent life-threatening hypoglycemia. Extensive investigations revealed elevated insulin and C-peptide levels, a pituitary microadenoma, and a somatostatin-avid gastric lesion, leading to the diagnosis of Multiple Endocrine Neoplasia type 1 (MEN-1). Management included dextrose infusions, somatostatin-analogue therapy, and supportive care. The case highlights the diagnostic challenges of MEN-1 in atypical presentations and resource-limited settings, underscoring the need for a multidisciplinary approach to treatment and psychosocial support.
Rehman, Z., Razaq, D. N., Baig, D. W. S., Anees, A., Abbas, Z., Afnan, Z., Khalid, H., Nasir, H. (2025). Unveiling Multiple Endocrine Neoplasia Type 1 (MEN-1) in a Young Pakistani Male with Recurrent Hypoglycemia: A Diagnostic Odyssey in a Resource-Limited Setting. Turkish Journal of Internal Medicine, Volume: 7 Issue: 4. https://doi.org/10.46310/tjim.1769251
Panzuto F, Barbi S, Trama A, Fazio N. The importance of education and training in neuroendocrine neoplasms: challenges and opportunities for multidisciplinary management. Cancer Treat Rev. 2025 Sept;139:102998.
Brandi ML, Pieterman CR, Lines KE, Stevenson M, Marini F, Cuny T, et al. Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice. Lancet Diabetes Endocrinol. 2025 Sep;13(9):665–82. doi:10.1016/S2213-8587(25)00119-6
Bruno Vergès, Françoise Boureille, Pierre Goudet, Arnaud Murat, Albert Beckers, Geneviève Sassolas, Patrick Cougard, Béatrice Chambe, Corinne Montvernay, Alain Calender, Pituitary Disease in MEN Type 1 (MEN1): Data from the France-Belgium MEN1 Multicenter Study, The Journal of Clinical Endocrinology & Metabolism, Volume 87, Issue 2, 1 February 2002, Pages 457–465, https://doi.org/10.1210/jcem.87.2.8145
Thakker R. V. (2010). Multiple endocrine neoplasia type 1 (MEN1). Best practice & research. Clinical endocrinology & metabolism, 24(3), 355–370. https://doi.or
Biermasz N. R. (2019). The burden of disease for pituitary patients. Best practice & research. Clinical endocrinology & metabolism, 33(2), 101309. https://doi.org/10.1016/j.beem.2019.101309.
Hofland J, Refardt JC, Feelders RA, Christ E, De Herder WW. Approach to the Patient: Insulinoma. J Clin Endocrinol Metab. 2024 Mar 15;109(4):1109–18.
Zhang WD, Liu DR, Wang P, Zhao JG, Wang ZF, Chen L. Clinical treatment of gastrinoma: A case report and review of the literature. Oncol Lett. 2016 May;11(5):3433–7.
Cheng S, Xu S, Guo J, He Q, Li A, Huang L, et al. Risk factors of central venous catheter-related bloodstream infection for continuous renal replacement therapy in kidney intensive care unit patients. Blood Purif. 2019;48(2):175–82. doi:10.1159/000495024.
Băicoianu-Nițescu LC, Gheorghe AM, Carsote M, Dumitrascu MC, Sandru F. Approach of Multiple Endocrine Neoplasia Type 1 (MEN1) Syndrome–Related Skin Tumors. Diagnostics. 2022 Nov 12;12(11):2768.
Haris B, Saraswathi S, Hussain K. Somatostatin analogues for the treatment of hyperinsulinaemic hypoglycaemia. Ther Adv Endocrinol Metab. 2020 Jan;11:2042018820965068.